Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy)
Condition(s):Precursor Cell Lymphoblastic Leukemia-lymphomaLast Updated:September 28, 2020Withdrawn
Hide Studies Not Open or Pending
Condition(s):Precursor Cell Lymphoblastic Leukemia-lymphomaLast Updated:September 28, 2020Withdrawn
Condition(s):GlioblastomaLast Updated:March 26, 2021Completed
Condition(s):Systemic Sclerosis; Scleroderma; Diffuse Systemic Sclerosis; Diffuse Scleroderma; Diffuse Cutaneous Systemic Sclerosis; Diffuse Cutaneous Scleroderma; Progressive Systemic Sclerosis; Progressive Scleroderma; Scleroderma, Systemic; Scleroderma, Diffuse; Scleroderma;Progressive; Systemic Sclerosis, Diffuse; Systemic; Sclerosis, Progressive; Scleroderma of Lung; Scleroderma With Pulmonary Involvement; Systemic Sclerosis Pulmonary; Systemic Sclerosis With Lung Involvement; Interstitial Lung Disease; Pulmonary Fibrosis InterstitialLast Updated:April 4, 2023Recruiting
Condition(s):Acute Lymphoblastic Leukemia in Complete Remission; Lymphoblastic Lymphoma in Complete Remission; Mixed Phenotype Acute Leukemia in Complete RemissionLast Updated:February 15, 2018Withdrawn
Condition(s):Immune Thrombocytopenia; Warm Autoimmune Hemolytic AnemiaLast Updated:October 28, 2019Withdrawn
Condition(s):Multiple Myeloma; Lymphoma; AmyloidosisLast Updated:January 31, 2023Active, not recruiting
Condition(s):Myeloid Hematologic Malignancy; Lymphoid Hematologic MalignancyLast Updated:September 27, 2022Completed
Condition(s):Multiple MyelomaLast Updated:February 10, 2023Recruiting
Condition(s):Liposarcoma; Malignant Peripheral Nerve Sheath Tumors; Alveolar Soft Part Sarcoma; Ewing Sarcoma; SarcomaLast Updated:November 27, 2020Withdrawn
Condition(s):Solid TumorsLast Updated:April 18, 2023Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.